SYRS

Syros Pharmaceuticals Inc

SYRS, USA

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

https://www.syros.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SYRS
stock
SYRS

$SYRS stock is up 126% today. Here's what we see in our data. Quiver Quantitative

Read more →
SYRS
stock
SYRS

Failed Clinical Trial Forces Syros Pharmaceuticals Into Delisting and Wind-Down Operations Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2024-09-30)

Rating:

HOLD

Target Price:

$8.75

Analyst Picks

Strong Buy

0

Buy

0

Hold

3

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.00

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

57.50 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.53 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 20.60% of the total shares of Syros Pharmaceuticals Inc

1.

Bain Capital Life Sciences Investors, LLC

(10.2493%)

since

2024/12/31

2.

BlackRock Inc

(1.0333%)

since

2024/12/31

3.

Vanguard Group Inc

(0.9994%)

since

2024/12/31

4.

Vanguard Institutional Extnd Mkt Idx Tr

(0.9602%)

since

2025/01/31

5.

Omega Fund Management LLC

(0.9364%)

since

2024/12/31

6.

Geode Capital Management, LLC

(0.7314%)

since

2024/12/31

7.

Affinity Asset Advisors, LLC

(0.559%)

since

2024/12/31

8.

Citigroup Inc

(0.5189%)

since

2024/12/31

9.

Qube Research & Technologies

(0.4553%)

since

2024/12/31

10.

TWO SIGMA SECURITIES, LLC

(0.4015%)

since

2024/12/31

11.

Fidelity Extended Market Index

(0.3638%)

since

2025/01/31

12.

Renaissance Technologies Corp

(0.3579%)

since

2024/12/31

13.

HRT FINANCIAL LLC

(0.3262%)

since

2024/12/31

14.

XTX Topco Ltd

(0.3036%)

since

2024/12/31

15.

State Street Corp

(0.2588%)

since

2024/12/31

16.

Jane Street Group LLC

(0.1972%)

since

2024/12/31

17.

Two Sigma Investments LLC

(0.1821%)

since

2024/12/31

18.

iShares Micro-Cap ETF

(0.1708%)

since

2025/02/28

19.

UBS Group AG

(0.1679%)

since

2024/12/31

20.

Extended Equity Market Fund K

(0.1668%)

since

2024/12/31

21.

Northern Trust Corp

(0.1521%)

since

2024/12/31

22.

Fidelity Total Market Index

(0.1484%)

since

2025/01/31

23.

1492 Capital Management, LLC

(0.1463%)

since

2024/12/31

24.

Virtu Financial LLC

(0.1222%)

since

2024/12/31

25.

Fidelity Series Total Market Index

(0.0884%)

since

2025/01/31

26.

Northern Trust Extended Eq Market Idx

(0.0842%)

since

2024/12/31

27.

NT Ext Equity Mkt Idx Fd - L

(0.0842%)

since

2024/12/31

28.

Baader Bank INC

(0.0823%)

since

2024/12/31

29.

NT Ext Equity Mkt Idx Fd - NL

(0.0627%)

since

2024/12/31

30.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0497%)

since

2024/12/31

31.

Spartan Total Market Index Pool E

(0.0443%)

since

2025/01/31

32.

Vanguard U.S. Eq Idx £ Acc

(0.0392%)

since

2025/01/31

33.

Fidelity Nasdaq Composite Index

(0.0273%)

since

2025/01/31

34.

State St US Extended Mkt Indx NL Cl C

(0.0255%)

since

2025/02/28

35.

Extended Equity Market Fund M

(0.0217%)

since

2024/12/31

36.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0201%)

since

2024/12/31

37.

NT Ext Eq Mkt Indx Fd DC Lend T4

(0.0201%)

since

2024/12/31

38.

1290 VT Micro Cap K

(0.018%)

since

2025/01/31

39.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.013%)

since

2024/09/30

40.

SSgA U.S. Total Market Index Strategy

(0.0104%)

since

2024/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

-0.1985

EPS Difference

0.1985

Surprise Percent

100%

Investing Fit Scorecard

(Last Updated 2024-09-30)

Deep Value
Weak Deep Value(2)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2024-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.